Oddo BHF - PSB Industries SA (PSB) Psb Industries : CA T2 lÃ©gÃ¨rement supÃ©rieur aux attentes

Report

Oddo BHF

Jeremy Garnier

Psb Industries : CA T2 lÃ©gÃ¨rement supÃ©rieur aux attentes

>CA T2 : 85.7Mâ‚¬ (vs. 79.9Mâ‚¬e) soit +2.0% yoy - PSB Industries a publiÃ© hier soir son CA T2 (retraitÃ© de la contribution du pÃ´le Agroalimentaire & Distribution qui avait atteint 13.3Mâ‚¬ au T2 2017) qui ressort au-dessus de nos estimations Ã 85.7Mâ‚¬ soit une hausse de 2.0% (vs. -4.9%e Ã 79.9Mâ‚¬e). Pour rappel, le groupe a finalisÃ© le 28 juin 2018 la cession du pÃ´le Agroalimentaire & Distribution (CA de 48Mâ‚¬, 12.7% du CA 2017) au groupe Faerch Plast.Sur le semest...

11/07/2018 4 FR

Underlying

PSB Industries SA

PSB Industries is a holding company. Co. is engaged in technological industries and is organized into the following three operating segments (business units): Beauty Packaging (Texen), Custom Packaging (CGL Pack), and Specialty Chemicals (Baikowski). Beauty Packaging (Texen) specializes in plastic injection and finishing, chiefly for the cosmetics and perfume industry; Custom Packaging (CGL Pack) specializes in the design and manufacture of custom thermoformed packaging for consumer products; and Specialty Chemicals (Baikowski) specializes in the production of powders and liquids based on ultra-pure alumina.

See profile

FR0000060329 Euronext Paris France

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Jeremy Garnier

Other Reports on these Companies

SmartInsider

PSB Industries: 1 director

A director at PSB Industries sold 5,074 shares at 30.000EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

Free Trial

May 18, 2021 May 18, 2021 1 EN

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - 04/23/2021

...

April 23, 2021 April 23, 2021 58 EN

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - 23/04/2021

...

April 23, 2021 April 23, 2021 58 FR

Sanofi : Le T1 2024 passe sans encombre

>Un peu supérieur aux attentes - Sanofi publie ce matin ses résultats du T1 24 qui s’avèrent un peu au-dessus des attentes au niveau des ventes et de son BPA. Comme attendu Sanofi bénéficie d’un effet changes très négatif (-4.3% en topline et -10.2% en bottom line). Brièvement, les ventes totales du groupe ressortent à 10 464 M€ vs 10 272 M€e (+2.4% ; +6.7% à tcc), son core EBIT à 2 843 M€ vs 2 748 M€e (-14.7% ; -4.2% tcc) pour un Core BPA de 1.78 € vs 1.71 €e e...

3m 3m 1 FR

Christophe Chaput

Christophe Chaput

SPIE : First quarter ahead of expectations and 2024 outlook confirmed

>Q1 revenue ahead of expectations: € 2,225.5m vs € 2,144.5m estimated - For its first quarter, the SPIE Group has reported revenue slightly ahead of expectations. Revenue increased by 11.6% to € 2,225.5m, compared with our estimate of € 2,144.5m (+3.8% difference) and the consensus estimate of € 2,167m (+2.7% difference). Most of the difference relates to organic growth, which was 6.2%, an excellent performance (we were expecting +4.3% and the consensus +5.2%). Acquis...

3m 3m 1 EN

Cor Kluis

Cor Kluis

Adyen NV : Revenue in line but no beat, better cost, lower price offset by more volume

>Conclusion: Revenue in line but no beat, better cost, lower price & more volume - In 1Q24 the net revenue growth of +21% was in line with out and market consensus, but there was no beat which the market often would appreciate. Further in Q1 Adyen had less FTE than expected indicating a better cost control. Further we see luckily see that Adyen is willing to accept a lower price which is offset by getting more volume/TPV also influenced by getting a larger part of it...

15m 15m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Psb Industries : CA T2 lÃ©gÃ¨rement supÃ©rieur aux attentes

PSB Industries: 1 director

ODDO BHF Small & MIDCAP MORNING NEWS - 04/23/2021

ODDO BHF Small & MIDCAP MORNING NEWS - 23/04/2021

Sanofi : Le T1 2024 passe sans encombre

SPIE : First quarter ahead of expectations and 2024 outlook confirmed

Adyen NV : Revenue in line but no beat, better cost, lower price offset by more volume

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe